Skip to main content

Table 1 Clinical outcome and country by treatment in 199 subjects involved in the CYP2D6 PGx analysis

From: Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

  TQ plus CQ (n = 134, total) PQ plus CQ (n = 31) CQ plus placebo (n = 34)
50 mg (n = 34) 100 mg (n = 35) 300 mg (n = 37) 600 mg (n = 28)
N, subjects (%) per treatment arm
Clinical outcome
 6 month relapse-free (n = 126) 18 (53) 17 (49) 32 (86) 26 (93) 23 (74) 10 (29)
 Relapsed (n = 73) 16 (47) 18 (51) 5 (14) 2 (7) 8 (26) 24 (71)
Country
 India (n = 3) 1 (3) 1 (3) 1 (3) 0 (0) 0 (0) 0 (0)
 Peru (n = 114) 20 (59) 21 (60) 19 (51) 16 (57) 18 (58) 20 (59)
 Thailand (n = 82) 13 (38) 13 (37) 17 (46) 12 (43) 13 (42) 14 (41)